Crotaline snake antivenom

Drug Profile

Crotaline snake antivenom

Alternative Names: Anavip; Crotaline snake antivenin - Rare Disease Therapeutics

Latest Information Update: 01 Jun 2010

Price : $50

At a glance

  • Originator Instituto Bioclon; Rare Disease Therapeutics
  • Developer Rare Disease Therapeutics
  • Class Antivenins; Fab fragments
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Snake venom poisoning
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Snake venom poisoning

Most Recent Events

  • 20 Jun 2005 Phase-II clinical trials in Snake venom poisoning in USA (Injection)
  • 20 Jan 2004 Crotaline snake antivenom [Anavip™] has received Orphan Drug Status for Snake venom poisoning in USA.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top